Dr Stephen Parker has over 30 years of corporate finance, directorship, corporate advisory and investment banking experience within the pharmaceutical and biotechnology sectors in the UK, Europe and North America. He is a non-executive chair of AIM-listed oncology therapeutics company Sareum Holdings, and a non-executive director of AIM-listed RNA-therapeutics focussed company, Silence Therapeutics. Dr Parker held senior consulting roles at a number of listed companies, and has investment banking experience at Baring Brothers, SBC Warburg Dillon Read and Apax Partners. He is FCA authorised, an affiliate of the Institute of Chartered Accountants in England & Wales (ICAEW), and a Fellow of the Royal Society of Chemistry and Royal Society of Medicine.
